Novartis received a scolding from the FDA for airing a television ad in 2022 that made false and misleading statements about the breast cancer drug Kisqali. The FDA claimed that Novartis referenced data in the ad that did not support the benefits of the medicine and failed to demonstrate that it helps preserve quality of life for patients. The agency expressed concern that the ad could mislead patients into believing that Kisqali is more effective in treating their condition and symptoms than was actually demonstrated. The FDA warned Novartis about the overstatement of the drug’s efficacy in the ad.
Source link
FDA scolds Novartis over a misleading TV ad for a breast cancer treatment
